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Summary
Wilms’ Tumour 1 (WT1) is a zinc finger transcription factor that is over-
expressed in acute myeloid leukaemia (AML). Its restricted expression in
normal tissues makes it a promising target for novel immunotherapies aim-
ing to accentuate the cytotoxic T lymphocyte (CTL) response against AML.
Here we report a phase I/II clinical trial of subcutaneous peptide vaccination
with two separate HLA-A2-binding peptide epitopes derived from WT1,
together with a pan-DR binding peptide epitope (PADRE), in Montanide
adjuvant. Eight HLA-A2-positive patients with poor risk AML received five
vaccination cycles at 3-weekly intervals. The three cohorts received 03, 06
and 1 mg of each peptide, respectively. In six patients, WT1-specific CTL
responses were detected using enzyme-linked immunosorbent spot assays
and pWT126/HLA-A*0201 tetramer staining, after ex vivo stimulation with
the relevant WT1 peptides. However, re-stimulation of these WT1-specific T
cells failed to elicit secondary expansion in all four patients tested, suggesting
that the WT1-specific CD8+ T cells generated following vaccination may be
functionally impaired. No correlation was observed between peptide dose,
cellular immune response, reduction in WT1 mRNA expression and clinical
response. Larger studies are indicated to confirm these findings.
Keywords: acute myeloid leukaemia, immunotherapy, tumour antigens,
trials.
The potential of T lymphocytes to eliminate leukaemia is
demonstrated by the graft-versus-leukaemia effect following
haematopoietic stem cell transplantation (Odom et al,
1978; Goldman et al, 1988; Horowitz et al, 1990). The iden-
tification of target antigens on leukaemic cells has renewed
interest in the use of peptide vaccines to stimulate leukae-
mia-specific T cell responses (Oka et al, 2004; Rezvani et al,
2008; Keilholz et al, 2009; Maslak et al, 2010; Kuball et al,
2011). A target antigen of particular interest is the zinc finger
transcription factor Wilms’ Tumour 1 (WT1), which is over
expressed in several solid tumours as well as acute myeloid
leukaemia (AML) and myelodysplasia (Inoue et al, 1997;
Miyoshi et al, 2002; Oji et al, 2002). WT1 has several charac-
teristics that render it a highly attractive target for immuno-
therapies: its expression in normal tissues is limited (Call
et al, 1990); it is expressed by leukaemic stem cells in addi-
tion to more mature myeloid cells (Saito et al, 2010); and its
expression increases as myeloid disease progresses (Cilloni
et al, 2003). WT1 is required for proliferation of leukaemia
cells (Algar et al, 1996), reducing the likelihood of tumour
escape by down-modulation of the antigen. We have previ-
ously shown that WT1-specific cytotoxic T lymphocytes
(CTLs) kill leukaemia cells and leukaemia stem cells without
affecting normal stem cell function (Gao et al, 2000, 2003).
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Although WT1 is expressed in normal tissues during
embryogenesis, immunological tolerance to WT1 is not
complete: WT1-specific CTLs have been detected and
expanded following exposure to the peptide both in healthy
donors (Rezvani et al, 2003) and in patients with AML
(Scheibenbogen et al, 2002). Recent studies have shown
immune and clinical responses with peptide vaccinations
against single epitopes of WT1 (Oka et al, 2004; Keilholz
et al, 2009); however, naturally occurring CD8+ T cell
responses against myeloid leukaemias target multiple epi-
topes, potentially enhancing the strength and diversity of
these responses (Gannage et al, 2005; Rezvani et al, 2005).
We have identified two distinct peptide epitopes of WT1
that are presented by HLA-A0201 (A2) and function as tar-
gets for leukaemia-reactive CD8+ CTL: pWT126 and
pWT235 (Bellantuono et al, 2002). We hypothesized that
the use of peptide vaccination with both epitopes would
result in a robust immunological response with reduced risk
of tumour escape. Here we report a phase I/II clinical trial
of peptide vaccination in HLA-A2-positive patients with
poor risk AML, using pWT126, pWT235 and the pan HLA-
DR T helper cell epitope (PADRE) together with Montanide
adjuvant.
Methods
Study design and patient population
This was a phase I/II multi-centre dose escalation trial in HLA-
A*0201-positive patients with poor risk AML. The primary
objectives of the study were to determine the safety and toxicity
profile of peptide vaccination with a combination of WT1 pep-
tides and PADRE in Montanide adjuvant, and to evaluate the
induction of autologous WT1-specific CTL responses; the sec-
ondary objective was to document any disease response. Details
of the clinical trial inclusion criteria are given in Table I.
The trial was approved by the UK National Research Ethics
Service and all participants gave written informed consent.
Vaccine preparation and administration
pWT126 (WT1 126–134: RMFPNAPYL), pWT235 (WT1
235–243: CMTWNQMNL) and PADRE [H-D-Ala-Cha
-Val-Ala-Ala-Trp-Thr-Leu-Lys-Ala-Ala-D-Ala-eAhx-Cys-OH
(Alexander et al, 1994)] peptides were synthesized to GMP
grade by Bachem UK Ltd. (St Helens, Merseyside, UK).
Peptides were reconstituted to 3 mg/ml in water with a
maximum dimethyl sulfoxide (DMSO) concentration of
25% v/v and stored at 20°C. On the day of injection, pep-
tides were thawed and a water-in-oil emulsion vaccine was
prepared by mixing the peptides in 1:1 ratio (aqueous
phase) with an equal volume of the adjuvant Montanide
ISA-51 (oil phase; Seppic, Puteaux, France). Vaccines con-
taining pWT126 with PADRE, and pWT235 with PADRE,
were administered subcutaneously within 4 h of prepara-
tion at two separate sites, to avoid competitive binding of
HLA-A*0201 by the WT1 peptides.
Dose escalation schedule
Three dose levels were used, comprising 03, 06 or 10 mg
peptide. One vaccination cycle comprised separate subcuta-
neous injections of 03/06/10 mg pWT126 + 03/06/10 mg
PADRE peptide, and of 03/06/10 mg pWT235 + 03/06/
10 mg PADRE peptide, each admixed with Montanide
ISA-51. Vaccination cycles were repeated every 3 weeks to a
maximum of five cycles. After three of three patients had
completed the initial 03 mg dose level with no evidence of
grade 3–4 toxicity attributable to vaccination, a further three
patients were treated at the 06 mg dose level. In the absence
of grade 3–4 toxicity at this level, further patients received
treatment at the 10 mg dose level.
Assessment of toxicity
At each outpatient visit, patients were evaluated for toxicities
according to the National Cancer Institute, COMMON TOXICITY
Table I. Inclusion criteria.
HLA-A*0201-positive
18–75 years
No fludarabine in previous 3 months
World Health Organization performance status 0–2
Life expectancy 6 months or greater
Haemoglobin ≥70 g/l; neutrophil count ≥02 9 109/l; lymphocyte count >05 9 109/l; platelet count ≥40 9 109/l
Serum bilirubin, alanine aminotransferase and/or aspartate aminotransferase <3 times upper limit of normal reference range
Creatinine clearance ≥30 ml/min
Patients NOT eligible for haematopoietic stem cell transplantation, with:
AML in CR2 or greater
Good and standard risk AML in CR1 or stable PR (<20% blasts) in patients >60 years
Poor risk AML in CR1 or PR (slow remitters and/or adverse cytogenetics)
AML at first relapse post-HCST in CR or PR following re-induction and consolidation
AML, acute myeloid leukaemia; CR, complete remission; CR1, first CR; CR2, second CR; PR, partial remission; HSCT, haematopoietic stem cell
transplantation.
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CRITERIA v2.0 (http://ctep.cancer.gov/protocolDevelopment/
electronic_applications/docs/ctcmanual_v4_10-4-99.pdf).
Dose limiting toxicity was defined as grade 3–4 non-haema-
tological toxicity, or grade 4 haematological toxicity, that had
been determined by defined criteria to be certainly or
probably related to the vaccine.
Detection of antigen-specific CD8+ T cells
WT1-specific T cells were detected by staining with phycoery-
thrin-conjugated HLA-A*0201-pWT126 tetramer (Beckman
Coulter, High Wycombe, Buckinghamshire, UK) or dextramer
(Immudex, Copenhagen, Denmark), allophycocyanin-conju-
gated antibody to CD3 and fluorescein isothyocyanate-conju-
gated antibody to CD8 (BD Biosciences, Oxford, UK), as
described previously (King et al, 2009). The multimers have
mutations in the alpha-3 domain of the major histocompati-
bilty complex (MHC) molecule that reduces binding to CD8
molecules. The frequency of WT1-specific T cells was
expressed as the percentage of gated CD3+ CD8+ T cells that
were HLA-A*0201-pWT126-positive. The detection limit of
this tetramer had previously been determined as 005% of via-
ble CD3+ CD8+ T cells in patients with breast cancer and pros-
tate cancer (Gillmore et al, 2006; King et al, 2009). Control
cytomegalovirus (CMV)-specific T cells were detected by
substituting the HLA-A*0201-pWT126 tetramer with HLA-
A*0201-NLV tetramer (Beckman Coulter). Flow cytometry
was performed on an LSRII flow cytometer (BD Biosciences)
and analysed using FacsDiva software (BD Biosciences).
Heparinized peripheral blood samples were obtained prior
to the first vaccination cycle, at weeks 3, 6, 9 and 12, and
after the last vaccination at weeks 15 and 18–20. Serial
cryopreserved mononuclear cell samples from each patient
were analysed simultaneously. As primary assay, WT1-spe-
cific T cells were detected by tetramer staining following 8 d
in culture with pWT126 peptide in the presence of interleu-
kin (IL) 2 and IL7 at 20 units/ml and 5 ng/ml respectively
(Roche, Welwyn Garden City, Herts, UK and R&D Systems,
Abingdon, Oxfordshire, UK), as described previously (King
et al, 2009). Induction of a T-cell response to WT1 vaccina-
tion was defined as an increase in frequency of tetramer-
positive CD8+ T cells of >15 times that at baseline, as in
previous studies (Oka et al, 2004).
Analysis of antigen-specific CD8+ T cell function in vitro
Functional analysis of WT1-specific T cell responses was car-
ried out by detection of c-interferon (IFN-c) secretion using
an enzyme-linked immunosorbent spot (ELISPOT) assay
(BD Biosciences), as described previously (King et al, 2009).
Autologous peripheral blood mononuclear cells (PBMC)
were used to present peptides to the expanded T cells. ELI-
SPOT assays were performed in triplicate, with each well
containing 2 9 105 autologous PBMC, 5 lmol/l pWT126 or
pWT235 peptide and 2 9 105 responder T cells. After incu-
bation for 20 h at 37°C, the cells were discarded and plates
were washed and developed with a second, biotinylated, anti-
body to human IFN-c and streptavidin-alkaline phosphatase,
according to the manufacturer’s instructions. ELISPOT wells
containing responder T cells and autologous PBMC with
irrelevant peptides served as negative controls. Stimulation of
5 9 104 responder T cells with 200 ng/ml of staphylococcal
enterotoxin B was used as a positive control. ELISPOT plates
were read using an AxioCamMRc plate reader and KS Elispot
software (Zeiss, Cambridge, UK). Results were expressed as
the mean number of spot-forming units per 106 cells from
triplicate wells, and a cytokine response was considered posi-
tive if the mean number of spot-forming units per 106 cells
was greater than two standard deviations above that in the
absence of cognate peptide.
The capacity of vaccination-induced WT1-specific CD8+ T
cells to undergo antigen-specific expansion ex vivo was mea-
sured by HLA-A*0201-pWT126 dextramer staining and flow
cytometric analysis following restimulation over 14 d: 3 9 106
responder T cells were incubated with 2 9 106 autologous
PBMC and 5 lmol/l peptide in culture medium supplemented
with 20 units/ml IL2 (Roche), 5 ng/ml IL7 (R&D Systems),
together with additional 10 ng/ml IL15 (R&D Systems) and
30 ng/ml IL21 (Peprotech, London, UK), as previously shown
(King et al, 2009) to maximize antigen-specific in vitro expan-
sion. pWT126 peptide was used as test peptide, with CMV
pp65 NLVPMVATV (NLV) peptide (ProImmune, Oxford,
UK) as positive control in CMV-responsive patients.
Measurement of WT1 mRNA levels by real-time
quantitative reverse transcription polymerase chain
reaction (qRT-PCR)
All samples for qRT-PCR were blinded. Total RNA was
extracted from PBMC and reverse transcribed using the stan-
dardized protocol developed within the Europe Against Cancer
(EAC) programme (Gabert et al, 2003). qRT-PCR assays were
performed on an Applied Biosystems ABI7900 instrument
(Applied Biosystems, Foster City, CA, USA) according to EAC
conditions, with standardized WT1-specific primers (Van Dijk
et al, 2002; Cilloni et al, 2009) and probes at final concentra-
tions of 300 and 200 nmol/l respectively (Gabert et al, 2003).
In patients with NPM1 mutations, the mutant transcript was
monitored by qRT-PCR in parallel with WT1, according to the
method of Gorello et al (2006). Reactions were performed in
triplicate wells with appropriate water controls. Expression of
the housekeeping gene ABL1 was used as the endogenous
cDNA quantity control for all samples (Cilloni et al, 2009).
Statistics
The pre-specified primary immunological trial objective was
to evaluate induction of autologous WT1-specific T cell
responses. Baseline and maximum post-vaccination responses
were compared using the paired two-tailed t-test. Spearman
B. J. Uttenthal et al
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q was used to correlate antigen-specific responses to pWT126
and pWT235 peptides. GraphPad Prism version 5.0 for
Windows (GraphPad Software, La Jolla, CA, USA) was used
for statistical analyses. P values of 005 or less were consid-
ered statistically significant.
Results
Patient characteristics
Demographics of the patients are shown in Table II. The
eight patients comprised three males and five females with
AML. The median age was 65 years (range 56–75 years). All
had received previous chemotherapy. At the start of vaccina-
tion, four were in morphological first complete remission
(CR1) (one with persistent cytogenetic abnormalities), one in
CR2 post-autograft, two in partial remission with 15% blasts
and one with slowly progressive disease.
Protocol administration and toxicity
Three patients received vaccination at the 03 mg dose level,
three at the 06 mg dose level and two at the 10 mg dose
level. Five patients completed all five vaccination cycles; two
received four cycles and one received two cycles, owing to
disease progression. No toxicity greater than grade 3 was
observed in any cohort; of note, no renal toxicity, no haema-
tological toxicity and no autoimmune phenomena were
attributable to vaccination. All patients developed local
reactions comprising erythema, swelling and induration of
up to grade 3 at vaccination sites, in one case requiring sub-
sequent vaccination to be deferred by 3 weeks. These results
indicate that vaccination with a combination of WT1 pep-
tides and PADRE in Montanide adjuvant is well tolerated.
Vaccination induces WT1-specific immune responses
Seven of eight patients were evaluable for assessment of T
cell response. PBMC samples were stained with HLA-
A*0201-pWT126 tetramer and analysed for circulating CD8+
T cells specific for WT1 using flow cytometry. Overall, the
frequency of WT1 tetramer-positive CD8+ T cells increased
from a median of 01% at baseline to a median of 045% at
maximum post-vaccination response (Fig 1A and B). Six of
seven patients showed an increase in frequency of WT1 tetra-
mer-positive CD8+ T cells >15 times that at baseline, a
criterion for response used in previous studies (Oka et al,
2004). However, the increase in WT1 tetramer-positive T
cells was not significant when the pre- and post-vaccination
data were analysed using a paired two-tailed t-test.
We next analysed functional CD8+ T cell responses to
pWT126, pWT235 and PADRE peptides by IFN-c ELISPOT.
Six of seven patients showed antigen-specific IFN-c responses
to all three peptides following vaccination (Fig 1C and
Table III), the earliest response being detected after a single
vaccination. Four of five patients in whom pWT126 and
pWT235-specific responses were detected continued to dem-
onstrate these responses at follow-up in weeks 15–18;
Table II. Patient characteristics.
Patient Sex
Age
(years)
Diagnosis
(morphological subtype)
Cytogenetics
at diagnosis Previous treatment Disease status pre-trial
RFH 001 Male 61 AML (M0) 46, XY, t(1;2)
(p32;p13)
ADE 3 + 10 (no response); FlAG-Ida
(to CR); FlAG; MACE
Morphological CR1;
MRD positive
RFH 002 Female 68 AML (M1) Failed DA + GO (to CR); DA CR1; low platelet count
RFH 003 Female 56 Secondary AML (M5) Normal MDS RAEB-1 treated with FlAG
(to CR1); DA; MACE; MidAC
Relapsed with AML
after 3 years: treated
with FlAG; FlAG-Ida
(to CR2); Bu/Cy ASCT.
CR2
UCH 001 Female 64 AML (M1) Normal DA 9 1; LD ara-C 9 3 Stable PR; 15% blasts
UCH 002 Female 65 AML (M1) Normal DA 9 1; LD ara-C 9 8 PR; 15% blasts
UCH 003 Female 75 AML (M4) Normal LD ara-C + GO 9 2
(to CR); LD ara-C 9 2
CR1
BHM 001 Male 66 AML 46, XY, der(7)
t(7;11) (q22;q13)
DA 9 1; MidAC 9 2 PR; slowly progressive
BHM 002 Male 68 AML (M0) Normal DA 9 2; MidAC 9 1 CR1
RFH, Royal Free Hospital, London; UCH, University College Hospital, London; BHM, Queen Elizabeth Hospital, Birmingham; AML, acute mye-
loid leukaemia; CR, complete remission; CR1, first CR; CR2, second CR; PR, partial remission; MRD, minimal residual disease; MDS RAEB-1,
myelodysplastic syndrome refractory anaemia with excess blasts-1; ADE, daunorubicin, cytarabine and etoposide; Bu/Cy ASCT, busulfan and
cyclophosphamide-conditioned autologous stem cell transplantation; DA, daunorubicin and cytarabine; FlAG, fludarabine, cytarabine and granu-
locyte colony-stimulating factor; GO, gemtuzumabozogamicin; Ida, idarubicin; LD ara-C, low-dose cytarabine; MACE, amsacrine, cytarabine and
etoposide; MidAC, mitoxantrone and cytarabine.
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however, one patient had lost pWT126- and pWT235-specific
responses. Responses to pWT126 and pWT235 were highly
correlated (P = 00008).
Vaccination-induced WT1-specific T cells do not expand
in vitro
We then examined the potential for WT1-specific CD8+ T
cells isolated from patients after vaccination to expand fol-
lowing re-challenge with the WT1 pWT126 peptide in vitro.
PBMC samples from four patients with at least four-fold
WT1 tetramer response were stimulated over 2 weeks in vitro
with WT1 pWT126 peptide or CMV pp65 NLV peptide.
Two of these patients were CMV IgG seropositive. Follow-
ing stimulation, both of these patients showed a two-fold
or greater increase in the frequency of CMV pp65-specific
CD8+ T cells (Fig 2). In contrast, WT1-specific CD8+ T
cells did not respond to stimulation (Fig 2 and data not
shown), indicating that the vaccine-induced WT1-specific
CD8+ T cells are unable to proliferate and expand upon
re-stimulation with peptide antigen in vitro.
Disease activity after vaccination
To assess the potential effect of vaccination on leukaemia,
WT1 mRNA expression was used as a surrogate marker of
minimal residual disease. In two patients, NPM1 mutations
were present, allowing disease progression to be assessed
independently of the targeted antigen.
In two of five evaluable patients (RFH001, RFH003),
the emergence of functional WT1-specific T cells after
vaccination at weeks 9 and 12 respectively, was followed
by a decrease in WT1 mRNA levels to below the upper
threshold limit observed in normal peripheral blood sam-
ples (Fig 3). Patients in whom there was no increase in
HLA-A*0201-pWT126 tetramer 
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Fig 1. WT1-specific CD8+ T cell response to vaccination. Tetramer
analysis of peripheral blood mononuclear cells was performed by
flow cytometry. Plots shown are gated on viable CD8+ T cells. Repre-
sentative data from Patient RFH003 (A) and maximal responses for
all patients (B) are shown. (C) Functional responses were assessed by
ELISPOT for c-interferon (IFN-c). Representative responses from
Patient RFH003 are shown.
Table III. Immunological and clinical response to vaccination.
Patient
Vaccine
dose
(mg)
Cycles
completed
Pre-trial WT1
tetramer
(% of CD8+)
Maximum
post-vaccination
tetramer (% of CD8+)
and time point
Tetramer
response >15
9 pre-trial?
IFN-c response by ELISPOT
Time from
start of study to
disease progressionpWT126 pWT235 PADRE
RFH 001 03 5 01 02
maximum week 9
+ + + + 9 months
RFH 002 10 4 01 02
maximum week 9
+ + + + 39 months
RFH 003 10 5 01 08
maximum week 12
+ + + + >41 months
UCH 001 03 5 N/A 14
N/A
N/A N/A N/A N/A 18 months
UCH 002 03 4 02 02
N/A
 + + + 9 weeks
UCH 003 06 5 00 05
maximum week 15
+ + + + 7 months
BHM 001 06 2 01 04
maximum week 6
+    6 weeks
BHM 002 06 5 00 42
maximum week 6
+ + + + 10 months
RFH, Royal Free Hospital, London; UCH, University College Hospital, London; BHM, Queen Elizabeth Hospital, Birmingham; ELISPOT,
enzyme-linked immunosorbent spot; N/A, not applicable.
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WT1-specific T cells, or in whom functional IFN-c
responses could not be detected, showed stable or increas-
ing WT1 mRNA levels. However, there was no correlation
between vaccine dose, emergence of WT1-specific T cells
or disease response.
Discussion
Vaccination with a combination of WT1 and PADRE pep-
tides in Montanide adjuvant was well tolerated and safe,
with no evidence of renal toxicity nor the haematological
toxicity that was previously observed in myelodysplastic syn-
drome patients in one study (Oka et al, 2003). The primary
immunological objective of this trial was the assessment of
WT1-specific CD8+ T cell responses following vaccination.
In accordance with the recommendations of the Society for
Biological Therapy (Keilholz et al, 2002), tetramer-based
quantitative assays and ELISPOT assays of function were
used to determine T cell responses. Both assays showed
responses to vaccination in six/seven patients (86%), a
response rate that compares favourably with that achieved in
other trials of WT1 peptide vaccination in AML (Oka et al,
2004; Rezvani et al, 2008; Keilholz et al, 2009; Maslak et al,
2010; Kuball et al, 2011). Using WT1 peptides with Monta-
nide adjuvant, several groups have reported immunological
responses in 625–875% of patients with AML in CR (Oka
et al, 2004; Rezvani et al, 2008; Maslak et al, 2010). In
patients with residual disease, Keilholz et al (2009) used
keyhole-limpet-haemocyanin (KLH) adjuvant with granulo-
cyte-macrophage colony-stimulating factor to enhance
immunogenicity, achieving WT1-specific tetramer responses
in 44%: it was suggested that this lower response rate might
be due either to an immunosuppressive effect of leukaemic
blasts or to responses falling below the limits of detection of
the assays used (Keilholz et al, 2009). In our study, immu-
nological responses were seen within 2 weeks of a single vac-
cination: similarly rapid responses have been observed
previously, suggesting that the vaccination-induced expan-
sion of self-restricted WT1-specific cells originates from pre-
existing memory CD8+ T cells (Oka et al, 2003; Rezvani
et al, 2008). However, we did not find these early immuno-
logical responses to correlate with clinical outcome, possibly
owing to the small sample size; only one group has previ-
ously been able to show a correlation between clinical and
immunological responses (Oka et al, 2004).
Importantly, we were unable to elicit secondary expansion
of WT1-specific CD8+ cells on re-stimulation with the cog-
nate pWT126 antigen in vitro. By contrast, CMV-specific
CD8+ T cells from the same patients exhibited robust poten-
tial for expansion, suggesting that the WT1-specific CD8+ T
cells generated following vaccination were functionally
impaired, or were of insufficient functional avidity. Such
antigen-specific T cell expansion is a key feature of immune
memory, and predicts tumour regression following cancer
vaccination in mice (Janssen et al, 2005; Rosato et al, 2006).
The failure of vaccination to establish functional immune
Fig 2. Vaccination-induced WT1-specific immune responses are short-lived. Peripheral blood mononuclear cells were isolated from two
pWT126/pWT235/PADRE-vaccinated, cytomegalovirus (CMV) IgG seropositive patients and re-stimulated with WT126 (WT1) or NLV (CMV)
peptides for 2 weeks. Frequencies of WT1- and CMV-specific CD8+ T cells were measured by dextramer staining and flow cytometric analysis.
Plots shown are gated on viable CD8+ T cells.
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memory may explain the transient nature of the immune
responses typically observed in cancer vaccination trials.
Rezvani et al (2011) recently found that initial WT1- and
PR1-specific T cell responses were lost in all patients follow-
ing repeated vaccination over 12 weeks; and although long-
term follow-up of three patients from the first trial of WT1
peptide vaccination has demonstrated persistence of WT1-
specific CD8+ T cells for over 8 years, in all cases these cells
were detectable before vaccination, raising the possibility that
their initial priming and expansion was a physiological
response to tumour rather than to vaccination (Tsuboi et al,
2011).
Different approaches have been used to provide CD4+ T
cell help following vaccination. In our study, PADRE peptide
was used to stimulate CD4+ T cells through MHC class II.
Both PADRE and WT1 peptides elicited an IFN-c response
following vaccination, suggesting that concurrent CD4+ and
CD8+ T cell responses were achieved, but this did not corre-
late with establishment of a memory response. Similarly, Ku-
ball et al (2011) were unable to demonstrate antigen-specific
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Fig 3. Disease response to vaccination with pWT126, pWT235 and PADRE peptides as measured by WT1/ABL1 mRNA quantification. Results
are shown for individual patients in complete remission (CR) (A) or partial remission (PR) (B) at the start of the trial. Expression of WT1
mRNA (solid, black squares) and, in patients with mutations in NPM1, NPM1 mutant mRNA (dashed, triangles) are shown as a ratio of the gene
of interest to ABL1. Months from the start of trial are shown on the X axis. Bold arrows denote times of vaccination and the time at which maxi-
mal tetramer responses were detected are given in the results section. The horizontal dotted line corresponds to the upper limit of WT1 expres-
sion in normal peripheral blood, as previously defined (Cilloni et al, 2009). RFH, Royal Free Hospital, London; UCH, University College
Hospital, London; BHM, Queen Elizabeth Hospital, Birmingham.
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T cell responses in any of four patients with AML who were
vaccinated with WT1, PR3 and PADRE peptides in Monta-
nide and CpG adjuvant; PADRE-specific CD4+ T cells in
their study were shown to lack the capacity to produce IL2,
a cytokine that is required for potent CD8+ T cell responses
to a vaccinated antigen.
The choice of adjuvant may also be important in deter-
mining the longevity of CD8+ T cell responses to vaccina-
tion. Following early murine experiments showing that
oil-in-water adjuvants, such as Incomplete Freund’s Adju-
vant (IFA) and Montanide adjuvant, could enhance immune
responses to peptide vaccination (Kast et al, 1993), Monta-
nide adjuvant has been used by our group and others in
clinical trials (Tsuboi et al, 2004; Rezvani et al, 2008;
Maslak et al, 2010; Kuball et al, 2011). However, sustained
systemic presentation of peptides from the oil-in-water
depot in the absence of a continuous helper/danger signal
may contribute to induction of CD8+ T cell tolerance, a
hypothesis formed by Bijker et al (2007) and reinforced by
their finding that substitution of IFA with phosphate-buf-
fered saline shortened the duration of antigen presentation
and resulted in durable CD8+ T cell responses to a minimal
CD8+ epitope.
Although we found that, in two patients, the emergence
of functional WT1-specific T cells after vaccination was fol-
lowed by a decrease in WT1 mRNA levels to below the
upper threshold limit observed in normal control samples,
there was no significant correlation between the immuno-
logical and disease responses to vaccination. This may
relate to the observation that secondary expansion of
WT1-specific T cells in vitro failed despite IL2, IL7, IL15
and IL21 cytokine cocktail and good CMV-specific T cell
expansion. It is well recognized that effective anti-tumour
activity of cytotoxic T cells correlates with high avidity for
tumour-associated antigens (Zeh et al, 1999; Dutoit et al,
2001; Yang et al, 2002); the lack of consistent clinical
response in our study may reflect a failure of vaccination
to result in sustained expansion of high-avidity WT1-spe-
cific T cell clones. Functional avidity using peptide titration
experiments was not tested in our study. In common with
other tumour-associated antigens, WT1 is expressed at low
levels in some normal tissues (Mundlos et al, 1993; Rama-
ni & Cowell, 1996; Baird & Simmons, 1997; Menssen et al,
1997), and high-avidity cytotoxic T cell clones may have
been deleted or rendered unresponsive during the establish-
ment of tolerance (Theobald et al, 1997; Nugent et al,
2000). In mice, repeated immunization with foreign anti-
gen generates memory CD8+ T cells that have increased
avidity for that antigen; in contrast, such avidity matura-
tion is limited for self antigen, such as WT1 (Turner et al,
2008). Similarly, antigen-specific memory CD8+ T cells in
patients vaccinated with a melanoma peptide failed to
acquire the enhanced functional avidity usually associated
with competent memory T cell maturation (Walker et al,
2008), while Rezvani et al (2011) demonstrated selective
deletion of high-avidity leukaemia-specific CD8+ T cells
following vaccination with WT1 and PR1 peptides.
Although early trials of peptide vaccination in cancer
patients showed promising immunological responses, more
recent reports have been predominantly negative (Kuball
et al, 2011; Rezvani et al, 2011). Our results illustrate further
the difficulties of expansion of high-avidity leukaemia-specific
effector and memory CD8+ T cell clones through vaccination
with short self-peptides, demonstrating that translational
studies are still required to define the site, time period, dose
and adjuvants that lead to optimal activation of both CD8+
and CD4+ T cell responses following delivery of peptide. The
low toxicity and relative simplicity of administration of pep-
tide vaccines remain attractive, with almost 100 open studies
of peptide vaccination currently listed on clinicaltrials.gov;
however, our data lend impetus to alternative strategies, such
as adoptive cellular immunotherapy with T cell receptor
gene-modified T cells, that have the potential to generate
potent antigen-specific cytotoxic responses against cancer
while circumventing the difficulties of peptide vaccination.
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